Choline Cognitive Performance Meta-analysis: What the Evidence Says

Quick Answer

Choline Cognitive Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• , Schizophrenia is characterized by delusions, hallucinations, disorganized thoughts, and cognitive dysfunction, with an estimated lifetime prevalence of 7.49 per 1000 people.The underlying pathophysiology is complex, with no single mechanism explaining the range of associated biological and behavioral abnormalities. [Fanshawe Jack B (2026); evidence level 1]
• Evidence from functionalH-MRS has highlighted changes in choline concentrations during cognitive tests thought to induce cholinergic signaling;H-MRS signal also strongly correlates with free choline but not membrane-bound phosphtidylcholine. [Fanshawe Jack B (2026); evidence level 1]
• It is commonly defined as the presence of clinically relevant depressive symptoms that do not meet the full diagnostic criteria for major depressive disorder (MDD) yet are associated with measurable distress and functional impairment. [Fleishhacker Filippo (2026); evidence level 4]
• Recent meta-analytic evidence indicates that subthreshold depressive symptoms affect nearly 15-20% of older individuals, with higher prevalence rates observed in primary care and institutional settings. [Fleishhacker Filippo (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For choline cognitive performance meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Fanshawe Jack B (2026). Variability and Magnitude of Choline Levels Across the Psychosis Spectrum: A Meta-analysis. DOI: 10.1093/schbul/sbag069. PMCID: PMC13158245. PMID: 42108701. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13158245/
• Fleishhacker Filippo (2026). Choline Alfoscerate in the Treatment of Subthreshold Depression in the Elderly: A Pilot Study (CARTESIO). DOI: 10.3390/jcm15114037. PMCID: PMC13258180. PMID: 42278899. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258180/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.